{
    "nctId": "NCT06273800",
    "briefTitle": "Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients",
    "officialTitle": "Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "pCR rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women with a new diagnosis of triple negative breast cancer who have not yet started systemic treatment.\n* Patients with stage I-III disease, patient with locoregional recurrence who have not been treated with chemotherapy before. ,\n* Aged \\< 60 years\n* Women having a (regular) physiological menstrual cycle\n* Patients who are assigned to receive neoadjuvant chemotherapy with or without immunotherapy, targeted therapy and endocrine therapy\n* Patients must be systemic treatment na\u00efve for current malignancy (e.g. no chemotherapy, hormonal therapy or targeted therapy)\n* Signed written informed consent\n\nExclusion Criteria:\n\n* current use of hormonal contraception or in the six weeks prior to start of neoadjuvant systemic treatment for breast cancer, such as:\n* Oral contraception (OAC)\n* Hormonal intra-uterine device (IUD, Mirena)\n* No ovarian function suppression to preserve fertility\n* Other forms of hormonal contraception, including but not limited to: nuva-ring, Implanon, prikpil\n* Currently pregnant and / or breast feeding. In case of use of hormonal contraception or breast feeding in de last year: patients should have had at least 2 menstrual cycles since stopping hormonal contraception.\n\n  - active other malignancy\n* IVF-trajectory for egg cell preservation prior to start of neoadjuvant systemic treatment",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}